ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 331 filers reported holding ROYALTY PHARMA PLC in Q4 2022. The put-call ratio across all filers is 0.58 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $554,117 | -1.7% | 20,417 | +11.3% | 0.03% | +3.3% |
| Q2 2023 | $563,956 | -10.4% | 18,346 | +5.0% | 0.03% | -23.1% |
| Q1 2023 | $629,444 | -24.7% | 17,470 | -17.4% | 0.04% | -27.8% |
| Q4 2022 | $835,453 | +2.3% | 21,140 | +4.0% | 0.05% | -8.5% |
| Q3 2022 | $817,000 | -17.6% | 20,323 | -13.8% | 0.06% | -6.3% |
| Q2 2022 | $992,000 | +3.3% | 23,587 | -4.2% | 0.06% | +57.5% |
| Q1 2022 | $960,000 | -9.1% | 24,630 | -7.1% | 0.04% | +14.3% |
| Q4 2021 | $1,056,000 | +12.1% | 26,499 | +1.6% | 0.04% | +9.4% |
| Q3 2021 | $942,000 | +208.9% | 26,073 | +250.5% | 0.03% | +220.0% |
| Q2 2021 | $305,000 | +4.5% | 7,439 | +11.3% | 0.01% | -9.1% |
| Q1 2021 | $292,000 | -17.5% | 6,685 | -5.4% | 0.01% | -26.7% |
| Q4 2020 | $354,000 | +28.3% | 7,069 | +7.6% | 0.02% | +7.1% |
| Q3 2020 | $276,000 | – | 6,569 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |